The company pays significant royalties (12-20% of net sales) for its largest product, which accounts for 15% of total revenue. This $2.4B annual cost puts significant pressure on profitability, incentivizing investment in solutions that can improve manufacturing efficiency, supply chain, or commercial operations.
Filing excerpt
Sales of the Company’s largest product, collectively DARZALEX (daratumumab) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), accounted for approximately 15.0% of the Company's total revenues for fiscal 2025.
What this signalsFilings often name leadership changes, deals and spending plans.
Vendors
sec-10kmarginPressureGet every 10-K signal for Johnson & Johnson and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Johnson & Johnson this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/e556307b-02cc-413a-a6f5-7ae1fbdfa13d returns this record as JSON. POST /v1/companies/enrich returns every signal for jnj.com.
{
"signal_id": "e556307b-02cc-413a-a6f5-7ae1fbdfa13d",
"signal_type": "sec-10k",
"signal_subtype": "marginPressure",
"detected_at": "2026-02-17T06:28:56.417+00:00",
"company": {
"name": "Johnson & Johnson",
"domain": "jnj.com"
},
"data": {
"detail": "The company pays significant royalties (12-20% of net sales) for its largest product, which accounts for 15% of total revenue. This $2.4B annual cost puts significant pressure on profitability, incentivizing investment in solutions that can improve manufacturing efficiency, supply chain, or commercial operations.",
"metrics": {
"pct": 0.15,
"pct_context": "of total revenues from DARZALEX",
"dollar_context": "Royalty amounts paid to Genmab for fiscal 2025",
"dollar_millions": 2400
},
"summary": "J&J paid $2.4B in 2025 royalties to Genmab for its top drug, DARZALEX.",
"excerpts": "Sales of the Company’s largest product, collectively DARZALEX (daratumumab) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), accounted for approximately 15.0% of the Company's total revenues for fiscal 2025.",
"relevance": 0.8,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/jnj-20251228.htm",
"filing_date": "2026-02-11",
"filing_year": 2026,
"fiscal_year_end": "12/28",
"sales_relevance": "Efficiency tools needed",
"signal_category": "financial",
"vendors_mentioned": [
"Genmab A/S"
]
}
}
curl https://signals.autobound.ai/v1/signals/e556307b-02cc-413a-a6f5-7ae1fbdfa13d \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"jnj.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.